Breathe Well Live Well
|
KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal …
The Herald | HeraldOnline.com KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma … |
View full post on asthma – Google News
|
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …
Sacramento Bee SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product … Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid … Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech … |
View full post on asthma – Google News
|
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for …
The Herald | HeraldOnline.com SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 — /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product … Rigel Pharma (RIGL) Starts Clinical Studies For Asthma, Discoid Lupus Rigel Begins Trial With Advanced Proprietary Therapeutic Product Candidates |
View full post on asthma – Google News
 InPharm |
GSK severe asthma drug progresses to Phase III
InPharm The Phase IIb DREAM study was testing mepolizumab in patients with severe eosinophilic asthma, a condition where organs are damaged by the over-production of white blood cells. The year-long study, which involved 621 patients, found the number of … GSK asthma drug cuts symptoms 52%; ready for PhIII GSK drug halves attacks in hard-to-treat asthma Drug 'could cut asthma A&E visits' |
View full post on asthma – Google News
|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
FierceBiotech MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova Reports Results Of A Phase 2b Trial Of MN-221 In Asthma Exacerbations |
View full post on asthma – Google News
|
Promising Phase II Data For Tiotropium In Adolescent Asthma Patients
Science 2.0 [1] Boehringer Ingelheim announced that the company has a comprehensive confirmatory phase III trial programme named UniTinA-asthma(TM) ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma. |
View full post on asthma – Google News
|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
MarketWatch (press release) MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News
|
Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical …
Benzinga … the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma, … |
View full post on asthma – Google News
 Daily Mail |
Positive SNG001 Phase II Asthma Clinical Trial Data
Science 2.0 (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial New drug 'reduces asthma symptoms' |
View full post on asthma – Google News
|
Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical …
MarketWatch (press release) … aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma (AEA), a long-lasting and severe form of asthma episode in which symptoms are unresponsive to initial bronchodilator or corticosteroid therapy. |
View full post on asthma – Google News